These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11401008)

  • 21. Vilazodone approved for major depression.
    Traynor K
    Am J Health Syst Pharm; 2011 Mar; 68(5):366. PubMed ID: 21330672
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat.
    Monti JM; Jantos H
    Eur J Pharmacol; 2006 Dec; 553(1-3):163-70. PubMed ID: 17059817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
    Khan A
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans.
    McAllister-Williams RH; Massey AE
    Psychopharmacology (Berl); 2003 Mar; 166(3):284-93. PubMed ID: 12589521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.
    Roberts C; Hagan JJ; Bartoszyk GD; Kew JN
    Eur J Pharmacol; 2005 Jul; 517(1-2):59-63. PubMed ID: 15978574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls.
    Seifritz E; Gillin JC; Rapaport MH; Kelsoe JR; Bhatti T; Stahl SM
    Biol Psychiatry; 1998 Jul; 44(1):21-33. PubMed ID: 9646880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects.
    Röschke J; Kögel P; Schlösser R; Wagner P; Mann K; Rossbach W; Benkert O
    Psychopharmacology (Berl); 1997 Jul; 132(1):44-9. PubMed ID: 9272758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram.
    Neckelmann D; Bjørkum AA; Bjorvatn B; Ursin R
    Behav Brain Res; 1996 Feb; 75(1-2):159-68. PubMed ID: 8800653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
    Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
    J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
    Sargent P; Williamson DJ; Pearson G; Odontiadis J; Cowen PJ
    Psychopharmacology (Berl); 1997 Aug; 132(3):296-302. PubMed ID: 9292630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sleep/waking and EEG power spectrum effects of a nonselective serotonin (5-HT) antagonist and a selective 5-HT reuptake inhibitor given alone and in combination.
    Bjorvatn B; Bjørkum AA; Neckelmann D; Ursin R
    Sleep; 1995 Jul; 18(6):451-62. PubMed ID: 7481417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor.
    Shelton J; Bonaventure P; Li X; Yun S; Lovenberg T; Dugovic C
    Neuropharmacology; 2009 Feb; 56(2):448-54. PubMed ID: 18948124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the selective activation of 5-HT3 receptors on sleep: a polysomnographic study in healthy volunteers.
    Staner L; Linker T; Toussaint M; Danjou P; Roegel JC; Luthringer R; Le Fur G; Macher JP
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):301-5. PubMed ID: 11532385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
    Tordera RM; Monge A; Del Río J; Lasheras B
    Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.
    Kuenzel HE; Steiger A; Held K; Antonijevic IA; Frieboes RM; Murck H
    Psychopharmacology (Berl); 2005 Jul; 180(2):327-32. PubMed ID: 15717211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers.
    Schlösser R; Röschke J; Rossbach W; Benkert O
    Eur Neuropsychopharmacol; 1998 Dec; 8(4):273-8. PubMed ID: 9928916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A; Millan MJ
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vilazodone: a new treatment option for major depressive disorder.
    Owen RT
    Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.